REFERENCES
1. Shimamoto K, Kita T, Mabuchi H, et al. J-LIT Study Group. Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: implications from the Japan Lipid Intervention Trial (J-LIT). Hypertens Res. 2007;30:119-23.
2. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290:2271-6.
3. Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler Thromb. 1993;13:1291-8.
4. Wiegman A, Gidding SS, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425-37.
5. Matsunaga K, Mizobuchi A, Ying Fu H, et al. Universal screening for familial hypercholesterolemia in children in Kagawa, Japan. J Atheroscler Thromb. 2022;29:839-49.
6. Talmud PJ, Futema M, Humphries SE. The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes. Curr Opin Lipidol. 2014;25:274-81.
7. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
8. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55:1121-6.
9. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331-7.
10. Jongh S, Ose L, Szamosi T, et al; Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231-7.
11. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74-80.
12. Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-56.
13. Nordestgaard BG, Chapman MJ, Humphries SE, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-90a.
14. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022. J Atheroscler Thromb. 2023;30:531-57.
15. Hasegawa N, Iwashima S, Furusawa Y, et al. assessment of low-density lipoprotein cholesterol levels and non-invasive vascular health in school-aged children: a study in Ogasa District, Shizuoka Prefecture. J Atheroscler Thromb. 2025;32:321-33.
16. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645-55.
17. Mikat-Stevens NA, Larson IA, Tarini BA. Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literature. Genet Med. 2015;17:169-76.
18. Jahn B, Santamaria J, Dieplinger H, et al. Familial hypercholesterolemia: a systematic review of modeling studies on screening interventions. Atherosclerosis. 2022;355:15-29.
19. Matsunaga K, Harada-Shiba M, Yamashita S, et al. A cost-effectiveness analysis for the combination of universal screening at 9-10 years old and reverse cascade screening of relatives for familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2025; doi: 10.5551/jat.65181.
20. Bae JH. Advancing familial hypercholesterolemia detection and management in South Korea. Korean Circ J. 2024;54:739-42.
21. CDC Blogs. Implementation science to improve case finding, cascade screening, and treatment for familial hypercholesterolemia: a prototype for precision public health research. Available from: https://blogs.cdc.gov/genomics/2020/05/05/implementation-science-3/ [Last accessed on 14 July 2025].
22. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet. 2005;13:401-8.
23. Pederiva C, Galimberti F, Casula M, et al. Diagnosis and screening strategies for detection of familial hypercholesterolaemia in children and adolescents in Italy: a survey from the LIPIGEN Paediatric Group. Children. 2025;12:288.
24. Fu HY, Matsunaga K, Inoue T, et al. Improved efficiency of the clinical diagnostic criteria for familial hypercholesterolemia in children: a comparison of the Japan Atherosclerosis Society Guidelines of 2017 and 2022. J Atheroscler Thromb. 2024;31:1048-57.
25. Tada H, Okada H, Nomura A, et al. Clinical diagnostic criteria of familial hypercholesterolemia- a comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network Criteria. Circ J. 2021;85:891-7.
26. Hendricks-Sturrup RM, Lu CY. Understanding implementation challenges to genetic testing for familial hypercholesterolemia in the United States. J Pers Med. 2019;9:9.
27. Schubert TJ, Gidding SS, Jones LK. Overcoming the real and imagined barriers to cholesterol screening in pediatrics. J Clin Lipidol. 2024;18:e297-307.
28. Yang JH, Cho KH, Hong YJ, Kim JH, Kim HY, Shin MH. Enhancing Familial hypercholesterolemia detection in South Korea: a targeted screening approach integrating national program and genetic cascade screening. Korean Circ J. 2024;54:726-38.
29. Safarova MS, Kullo IJ. Lessening the burden of familial hypercholesterolemia using health information technology. Circ Res. 2018;122:26-7.
30. Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023;20:845-69.
31. Jones LK, Walters N, Brangan A, et al. Patient experiences align with the familial hypercholesterolemia global call to action. Am J Prev Cardiol. 2022;10:100344.
32. Kusters DM, Avis HJ, de Groot E, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014;312:1055-7.
33. Elis A, Zhou R, Stein EA. Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiol Young. 2014;24:437-41.
34. Langslet G, Bogsrud MP, Halvorsen I, et al. Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. J Clin Lipidol. 2015;9:778-85.
